“I am saddened to be leaving Oncopeptides at a time when the promise of Pepaxti for patients with Multiple Myeloma is truly coming to fruition. I am leaving to take up a senior executive role at a large pharmaceutical company but am very glad to be handing over the running of the company to my CCO Sofia Heigis who has been the key driver of the commercialization efforts to date. Sofia will be Oncopeptides CEO as of today and I will secure a smooth transition in the coming weeks. I look forward to seeing the continued growth of Oncopeptides” said Monica Shaw.

Chairman Per Wold-Olsen said, “While I am sad to see Monica leave Oncopeptides, I fully understand the opportunity she is moving for and I am glad we have an excellent internal candidate in Sofia who can continue in the spirit of what has been built over the last months. With the transition to Sofia, Oncopeptides will continue to focus on the commercialization of Pepaxti which has already started in Germany, Austria, Switzerland, and Greece. We look forward to expanding the opportunity of Pepaxti to address the unmet need that continues to exist for patients with Multiple Myeloma.”

“I am truly excited to continue my journey at Oncopeptides, moving from the CCO role where I have built our commercial organization to the CEO role where I will continue our drive to become a profitable company. With our flagship product Pepaxti we have an opportunity to support patients with a product that provides efficacy, tolerability without compromise of quality of life” says Sofia Heigis.